Linked Life Data

15175435

Source:http://linkedlifedata.com/resource/pubmed/id/15175435

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
23
pubmed:dateCreated
2004-6-3
pubmed:abstractText
Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has shown promising preclinical and clinical activity against metastatic colorectal cancer, particularly in combination with chemotherapy.
pubmed:grant
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1533-4406
pubmed:author
pubmed:copyrightInfo
Copyright 2004 Massachusetts Medical Society
pubmed:issnType
Electronic
pubmed:day
3
pubmed:volume
350
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2335-42
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
2004
pubmed:articleTitle
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
pubmed:affiliation
Duke University, Durham, NC, USA. hurwi004@mc.duke.edu
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, U.S. Gov't, P.H.S., Randomized Controlled Trial, Multicenter Study, Clinical Trial, Phase III